Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
72 hedge funds and large institutions have $66.6M invested in Rubius Therapeutics, Inc in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 28 reducing their positions, and 58 closing their positions.
3,300% more call options, than puts
Call options by funds: $34K | Put options by funds: $1K
32% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 28
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less funds holding
Funds holding: 117 → 72 (-45)
72% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 58
87% less capital invested
Capital invested by funds: $494M → $66.6M (-$427M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.19M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$680K |
| 3 |
Millennium Management
New York
|
+$657K |
| 4 |
Two Sigma Investments
New York
|
+$567K |
| 5 |
Two Sigma Advisers
New York
|
+$518K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$16.2M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.45M |
| 3 |
JP Morgan Chase
New York
|
-$4.21M |
| 4 |
BlackRock
New York
|
-$3.49M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$2.29M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QCG
126
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$1K | -162 | Closed |
|
127
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -150 | Closed |
|
128
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$1K | -112 | Closed |
|
RUBY Hedge Fund Activity: Q2 2022 in Review
72 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q2 2022, worth a combined $66.6M — down 87% from $494M a quarter earlier.
Sellers outnumbered buyers: 58 funds closed out of RUBY and 16 opened new positions — a net loss of 42 holders — while 28 trimmed existing stakes and 19 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.19M. The largest seller was Victory Capital Management, exiting entirely with an estimated $16.2M sold.
- 72 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q2 2022, down from 117 in Q1 2022.
- Funds reported $66.6M of Rubius Therapeutics, Inc stock for Q2 2022, down 87% quarter-over-quarter.
- 16 funds opened new Rubius Therapeutics, Inc positions in Q2 2022 and 58 closed out, a net change of -42 holders.
- The largest Rubius Therapeutics, Inc buyer in Q2 2022 was Renaissance Technologies, an estimated $1.19M added.
- The largest Rubius Therapeutics, Inc seller in Q2 2022 was Victory Capital Management, an estimated $16.2M sold.
Based on aggregated 13F filings for Q2 2022.